Ascentage Pharma
Global biopharmaceutical company developing therapies that target apoptosis and other cancer pathways.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Selected active clinical trials
Phase 3 · Recruiting · CLL/SLL
A Study of Olverembatinib in SDH-deficient GIST.Phase 3 · Recruiting · GIST
Study of Olverembatinib (HQP1351) in Patients With CML-CPPhase 3 · Recruiting · Chronic Myeloid Leukemia
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Phase 3 · Recruiting · CLL/SLL
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)Phase 3 · Recruiting · Ph+ ALL
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid LeukemiaPhase 3 · Recruiting · Acute Myeloid Leukemia
Selected patent records
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/ascentage-pharma/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.